Compare Inovio Pharmaceuticals Inc (INO) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Upwork Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: Upwork Inc is far larger — about 9.5× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Upwork Inc for 38 Days on average.
| INO | UPWK | |
|---|---|---|
Market Cap | $112.19M | $1.07B |
Volume | 3,201,278 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $2.65 | $22.11 |
52-Week Low | $0.66 | $7.84 |
Typical Hold Time | 43 Days | 38 Days |
Enterprise Value | $83.51M | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
UPWK trades at $8.57, up 2.02% today, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing on revenue guidance, leading to a recent stock decline. Fundamentals show strong profitability with a 77.21% gross margin and 12.93% net income margin, while valuation ratios like P/E of 10.99 and P/S of 1.48 appear reasonable. Recent news highlights insider selling and ongoing securities fraud investigations.
The outlook for UPWK is cautious due to AI-driven competitive threats and weak guidance, though low valuation provides downside protection. Risks include declining active clients and legal scrutiny, but analyst consensus remains bullish with a $9.64 price target. Investment opportunity hinges on execution amid industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
